Table 2.
ACEI/ARB (n=83,044) | ORAL DM (n=54,488) | STATINS (n=90,020) | |
---|---|---|---|
Age (ref: 65-69) | |||
70-74 | 0.99 | 1.00 | 1.01 |
75-79 | 0.99* | 0.98** | 1.01 |
80-84 | 0.97*** | 0.97*** | 1.01 |
85+ | 0.97*** | 0.95*** | 1.00 |
Female | 1.00 | 0.98*** | 0.96*** |
Race/Ethnicity (ref: White) | |||
Hispanic | 0.97*** | 0.98** | 0.95*** |
American Indian/Alaska Native | 0.99 | 0.96 | 0.95 |
Asian | 1.00 | 1.01* | 1.00 |
Native Hawaiian/Pacific Islander | 0.92** | 0.98 | 0.93* |
Black | 0.96*** | 0.93*** | 0.91*** |
Missing Race | 1.02*** | 1.02** | 1.01 |
Census Block Group Median Household Income (ref: <$30,000) | |||
$30,000-$49,999 | 1.00 | 1.00 | 1.01 |
$50,000-$69,999 | 1.00 | 1.00 | 1.01 |
$70,000-$89,999 | 1.00 | 1.01 | 1.02* |
$90,000+ | 1.00 | 1.00 | 1.02* |
Census Block Group Percentage of Adults with a Bachelor's Degree or Higher Degree (ref: <15%) | |||
15-24% | 1.00 | 1.00 | 1.00 |
25-49% | 1.01 | 1.01 | 1.01 |
50%+ | 1.00 | 1.00 | 1.00 |
Number of Medications at Study Start | 1.01*** | 1.02*** | 1.02*** |
Mean Days Supply of Drugs in Therapeutic Category in 2010 (ref: <31) | |||
31-60 | 1.12*** | 1.23*** | 1.11*** |
61-90 | 1.35*** | 1.48*** | 1.47*** |
>90 | 1.61*** | 1.61*** | 1.61*** |
Percentage of Drugs in Therapeutic Category Refilled Via Mail Order Pharmacy in 2010 (ref: 0%) | |||
1%-50% | 1.01 | 1.01 | 1.01 |
51%-100% | 1.07*** | 1.06*** | 1.07*** |
Generic Drug Co-Payment for 30 Day Supply in 2010 (ref: >$10) | |||
$0-$10 | 1.02** | 1.02** | 1.02** |
Annual Individual Out-of-Pocket Maximum in January 2010 (ref: >$2,000) | |||
$0-$2,000 | 1.02*** | 1.01** | 1.02*** |
Interaction of: Percentage Refilled via Mail Order Pharmacy × Race | |||
51%-100% × Black | 1.02 | 1.05* | 1.05** |
51%-100% × Hispanic | 1.03** | 1.01 | 1.04** |
Statistically significant at p<0.05
p<0.01
p<0.001
Notes: (1) Models adjusted for HMO site and whether patient was enrolled in health plan for all 12 months of 2010; (2) 3,076, 2,141, and 3,256 observations with missing values for census block group variables and generic drug co-payment excluded from ACEI/ARB, ORAL DM, and STATINS regressions, respectively.